Tagged with M

Arch Pharmalabs Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD company with 11 manufacturing plants. What triggered the acquisition of the Hyderabad plant, and what have been the main milestones…

Merck Czech Republic Mr. Bartoš, you are celebrating your 15th anniversary with Merck this year, and your international career has offered you the opportunity to work throughout Europe. Over these years, how have you seen the 344-year-old Merck evolve and strengthen as a company, and how is this strength reflected here in the…

Merck Serono Turkey Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…

AbMax You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came back to China ? I first went to the US in 1986 to pursue the American Dream. At that time,…

European Union Chamber of Commerce in China The Chamber recently released this year’s European Business in China Business Confidence Survey – what were some of its key takeaways? There are four main points to the Survey. The first has to do with not only China but the rest of the world. China’s growth has been stronger than…

Janssen Pharmaceutica Can you please start by giving to our readers an overview of your background and your involvement with Janssen? I am a Public Health graduate and have completed an MBA program, so I have a combination of science and business. I have been with the Pharma industry for over 20…

Johnson&Johnson Romania In order to provide our readers with a general idea of the current state of the Romanian pharmaceutical and healthcare sectors, can you first of all elaborate on the key particularities of this market? Romania has been a member of the EU since 2009, is a potential member of the…

Nycomed Poland As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous year, but still managed to grow by 3,3% according to IMS data, which is in line with the market. This…

GlaxoSmithKline pharmaceuticals S.A. In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your entire professional career to GlaxoSmithKline (GSK), that you joined in 1992. What has kept you within the group, what has…

polski holding farmaceutyczny (PHF) Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was to privatise the three entities. You joined in March 2008, at a time when, if I may say, major steps…

Polpharma SA For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to the benefit of MNCs. How has the arrival of GSK, Teva or Sandoz, altered the playing field for the company…

Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…